Keyword: Gardasil

Merck's Gardasil 9 has been on an upward trajectory, but high global demand for the HPV shot has created a shortage for U.K. private clinics.

The relatively low vaccination rate among men is partly because it was first viewed as guarding against cervical cancer, said the study's lead author.

Here is some other vaccine news of note for the week.

Despite new challenges in shingles, Merck's vaccine business kept churning in 2017, generating sales of $6.5 billion—an increase of 4.8%.

Serum Institute of India plans to launch four vaccines in the coming years for pneumococcal, HPV, meningococcal and dengue.

A study published in Pediatrics showed that protection of Merck's Gardasil lasts over 10 years.

Merck's star HPV vaccine missed sales expectations in the third quarter as the company had to borrow from the CDC stockpile to fulfill orders. 

A large-scale phase 3 study shows that Merck's Gardasil 9 vaccine protects against HPV-related cancers for at least six years.

Efforts to boost the national HPV vaccination rate are yielding some positive results, new data from the CDC show.

GSK has formed an alliance with China’s e-commerce giant Alibaba to help promote HPV vaccine Cervarix.